Company intelligence / Profile preview

SIRION Biotech

Graefelfing, Bavaria, Germany

Ownership: Private
Employees: ~75
Development stage: Other

Overview

SIRION Biotech's viral vector technologies, particularly LentiBOOST®, are being used in over 18 clinical trials (including >20 Phase I/II and III) and have enabled a stem cell product approval to treat anemias; they provide optimized viral vectors for efficient cell and gene therapy, with a focus on improving transduction, safety, and clinical outcomes

Therapeutic areas: Infectious DiseasesHematologyOtherOncologyNeurology
Modalities: Gene therapyViral vectorCell therapyVaccineRNA therapy
Industry: Drug Discovery Services

Beyond the preview

Go deeper on SIRION Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIRION Biotech.

Explore the full profile